Business Wire

GSMA Mobile World Congress: Expert Group Presents Broadband Commission with Solutions for Closing the Broadband Gap

Del

An Expert Group of members of The Broadband Commission for Sustainable Development today released the report “A New Deal: Investing in Our Common Future – Policy Recommendations to Close the Broadband Gap”. The report contains recommendations for policymakers, regulators and the private sector to address the “unacceptable, persisting digital exclusion” of half the world’s population.

Formed of private sector and government representatives, the Expert Group was convened by The Broadband Commission for Sustainable Development in March 2017 to identify specific steps that need to be taken to close the ongoing gap in broadband coverage and usage.

Their report sets out specific actions for policymakers and regulators, addressing four key themes:

  • Healthy investment climate – including better broadband policy planning, stable regulatory conditions, and a smart strategy for generating public-sector revenue instead of targeted ICT taxes and fees.
  • Lower infrastructure supply costs – including greater sharing of telecommunications infrastructure and radio spectrum among operators; easier access to public infrastructure, rights of way and utility-owned fibre; openness to multi-technology approaches; release of more radio spectrum at lower cost and more flexible spectrum licensing.
  • Better functioning ICT markets – including completing market liberalisation, particularly in international services, and ensuring that competition is effective, including a fair return for regulated access to dominant operators’ infrastructure; using new forms of partnership and innovative technologies; improving transparency and efficiency of universal service schemes and maximizing the opportunity of convergence, allowing all types of services over any network.
  • Liberating demand for the wider digital economy to encourage supply and investment – including government digital strategies, an enabling and risk-based approach to use and protection of data, and minimal restrictions on data and content crossing borders.

“In our increasingly digital world, connectivity is the difference for many people between accessing employment, education, healthcare, e-banking and being left behind,” said Mr. Houlin Zhao, ITU Secretary General and Co-Vice Chair of the Broadband Commission. “The important set of recommendations presented in the Expert Group’s report provide concrete actions that can be considered to fast-forward broadband delivery of digital connectivity. In particular, we need to create an enabling policy and regulatory environment that will attract investment in ICTs, especially from the private sector.”

The Expert Group was chaired by Mr Philipp Metzger, Director General, Federal Office of Communications (OFCOM), Switzerland.

Metzger said: “Things don’t just happen – they are made to happen. This holds true for the broadband gap and how we can close it. The policy recommendations included in this report are very concrete; they address pressing issues that are hampering the roll-out of digital networks and services to people who desperately need them. This report is the result of a truly multi-stakeholder effort by committed experts who, regardless of whether they come from the public or the private sector, have gone out of their way to jointly propose solutions that will bring the benefits of digital connectivity to everyone, everywhere.”

The other members of the Expert Group were (in alphabetical order): Mr Scott Gegenheimer, Group Chief Executive Officer, Operations, Zain Group; Mr Mats Granryd, Director General, GSMA; Dr Carlos Jarque, América Móvil; Mr Mark MacGann, Group Chief Corporate & Public Affairs Officer, VEON; Mr Kevin Martin, Vice President, Mobile and Global Access Policy, Facebook; Mr Paul Mitchell, Senior Director, Technology Policy, Microsoft; Hon Jean Philbert Nsengimana, former Minister of Youth and ICT, Rwanda; Mr Denis O’Brien, Chairman, Digicel Group.

Download the report at: http://www.broadbandcommission.org/publications/Pages/Expertgroupreport-2018.aspx.

About the GSMA

The GSMA represents the interests of mobile operators worldwide, uniting nearly 800 operators with more than 300 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces industry-leading events such as Mobile World Congress, Mobile World Congress Shanghai, Mobile World Congress Americas and the Mobile 360 Series of conferences.

For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.

Contact information

GSMA Press Office
Georgie Callé
pressoffice@gsma.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Octapharma announces approval of new Nuwiq® product strengths in Europe, increasing dosing flexibility for patients with haemophilia A18.6.2018 07:06Pressemelding

Octapharma announced today that the European Medicines Agency (EMA) has approved an extension of marketing authorisation for its human cell line-derived recombinant factor VIII (rFVIII) product, Nuwiq®. New single dose vial strengths of 2500, 3000 and 4000 International Units (IU) will be available in Europe, in addition to the current strengths of 250, 500, 1000 and 2000 IU. The new Nuwiq® vial strengths have been available in the US since September last year, following approval by the FDA. Nuwiq® is indicated in adults and children of all ages for on-demand treatment and prophylaxis, including during surgery, to prevent and control bleeding episodes in patients with haemophilia A. This expanded array of vial strengths has the potential to increase treatment options for patients with haemophilia A by improving dosing flexibility. Patients who previously required more than one vial per infusion may be able to reduce the number of vials needed. Nuwiq® is the only rFVIII available in an

STATS and SpokeHub Partner to Power Deeper, More Meaningful Conversations Around the 2018 FIFA World Cup18.6.2018 07:00Pressemelding

Today, STATS, the worldwide leader in sports data and intelligence, and SpokeHub announced a new partnership to bring STATS Insights to SpokeHub’s social engagement platform, connecting worldwide World Cup football (soccer) fans with content that is more impactful. Download the app today to see the match scores, player insights, and engage with World Cup fans everywhere! STATS Insights leverages more than 37 years of research experience to deliver deep historical and comparative statistical insights, play-by-play descriptions and in-game trends based on events as they happen in the match. Before, during and after each match, SpokeHub will harness STATS Insights to amplify conversations among World Cup football communities. During the game, live Insights will deliver trends on players and teams based on in-game events, statistics and milestones. “No sporting event gets global attention like the World Cup, and every fan is looking for deeper analysis around their favorite teams and playe

Celltrion Completes Resubmission to FDA for Proposed Trastuzumab Biosimilar18.6.2018 02:53Pressemelding

Celltrion (KRX:068270) has made a resubmission to the FDA (U.S. Food and Drug Administration) to obtain its marketing approval for CT-P6, a proposed mAb biosimilar to Herceptin® (trastuzumab). Celltrion submitted its abbreviated Biologics License Applications (aBLAs) for CT-P10 and CT-P6 to the FDA in April and May of last year, respectively. However, it received CRLs (complete response letters) from the FDA related to the warning letter issued by the FDA in January 2018, related to the manufacturing facility in Incheon, South Korea. Celltrion had completed the resubmission for the approval of CT-P10, a proposed biosimilar to Rituxan® (rituximab) last month. In accordance with FDA regulations, the approval procedure will be usually finalized within six months from the resubmission, so Celltrion expects the approval for the U.S. market of the two proposed biosimilars within this calendar year. FDA has notified Celltrion of its re-inspection schedule regarding regular audit results, and

CES Asia: Innovation at the Speed of 5G15.6.2018 14:59Pressemelding

CES Asia® 2018 wrapped today with the rapid pace of global innovation front and center over the show’s three day duration. The next stage of technology advancements were showcased across vehicle tech, robotics, artificial intelligence (AI), virtual and augmented reality, digital health and more. The event, 24 percent larger than last year in terms of footprint, cemented itself as the place to fully experience how the pace of technology is accelerating globally. CES Asia, the premier event for tech innovation in the Asian marketplace, will return to Shanghai, China, June 11-13, 2019. “5G and AI are igniting growth across the entire tech ecosystem changing the way we interact with technology and the world around us,” said Gary Shapiro, president and CEO, Consumer Technology Association (CTA)™. “It’s incredible to see technology refining and reinventing itself at such a fast pace. Just six months ago we were at CES with life-altering tech all around us. This week, I saw that technology re

bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association15.6.2018 10:00Pressemelding

bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, will be presented in an oral session on June 16 at the 23rd Annual Congress of the European Hematology Association by Franco Locatelli, M.D., Ph.D., of the IRCCS Ospedale Pediatrico Bambino Gesù of Rome, Italy. “The maturing data from HGB-204 and HGB-207 suggest that one-time treatment with LentiGlobin may address the underlying genetic cause of TDT. With our refined manufacturing process, the majority of patients with TDT and non-β0/β0 genotypes are transfusion-free and producing total hemoglobin at normal or near-normal levels,” said David Davidson, M.D., chief medical officer, bluebird bio. “We are on track to submit a m

bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association15.6.2018 10:00Pressemelding

bluebird bio, Inc. (Nasdaq: BLUE) today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease (SCD) will be presented in an oral presentation on Saturday, June 16 at the 23rd Congress of the European Hematology Association (EHA) by Julie Kanter, M.D., Medical University of South Carolina, Charleston, South Carolina. “The consistent production of increased amounts of anti-sickling HbAT87Q in the Group C patients reflects the substantial positive impact of the changes introduced with the amended HGB-206 study protocol and refined manufacturing process. All four Group C patients with greater than or equal to three months follow-up are making over 30 percent anti-sickling HbAT87Q. The first patient treated, now with six months of follow-up, is producing over 60 percent anti-sickling HbAT87Q with a normal total hemoglobin level of 14.2 g/dL,” said David Davidson, M.D., ch